{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T20:27:05Z","timestamp":1783542425905,"version":"3.55.0"},"reference-count":20,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2022,4,30]]},"DOI":"10.5582\/ddt.2022.01031","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T22:09:37Z","timestamp":1650492577000},"page":"93-95","source":"Crossref","is-referenced-by-count":6,"title":["Suppressing leukocyte Kv1.3-channels by commonly used drugs: A novel therapeutic target for schizophrenia?"],"prefix":"10.5582","volume":"16","author":[{"given":"Yasuhiro","family":"Sato","sequence":"first","affiliation":[{"name":"Miyagi University, School of Nursing, Taiwa-cho, Miyagi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Kuwana","sequence":"additional","affiliation":[{"name":"Miyagi University, School of Nursing, Taiwa-cho, Miyagi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itsuro","family":"Kazama","sequence":"additional","affiliation":[{"name":"Miyagi University, School of Nursing, Taiwa-cho, Miyagi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. Lancet. 2022; 399:473-486.","DOI":"10.1016\/S0140-6736(21)01730-X"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018; 17:341-356.","DOI":"10.1002\/wps.20567"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Muller N. Inflammation in schizophrenia: Pathogenetic aspects and therapeutic considerations. Schizophr Bull. 2018; 44:973-982.","DOI":"10.1093\/schbul\/sby024"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Fond G, Lancon C, Korchia T, Auquier P, Boyer L. The role of inflammation in the treatment of schizophrenia. Front Psychiatry. 2020; 11:160.","DOI":"10.3389\/fpsyt.2020.00160"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Faugere M, Micoulaud-Franchi JA, Alessandrini M, Richieri R, Faget-Agius C, Auquier P, Lancon C, Boyer L. Quality of life is associated with chronic inflammation in schizophrenia: a cross-sectional study. Sci Rep. 2015; 5:10793.","DOI":"10.1038\/srep10793"},{"key":"6","unstructured":"6. Semiz M, Yildirim O, Canan F, Demir S, Hasbek E, Tuman TC, Kayka N, Tosun M. Elevated neutrophil\/lymphocyte ratio in patients with schizophrenia. Psychiatr Danub. 2014; 26:220-225."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Miller BJ, Goldsmith DR. Evaluating the hypothesis that schizophrenia is an inflammatory disorder. Focus (Am Psychiatr Publ). 2020; 18:391-401.","DOI":"10.1176\/appi.focus.20200015"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kazama I. Physiological significance of delayed rectifier K<sup>+<\/sup> channels (Kv1.3) expressed in T lymphocytes and their pathological significance in chronic kidney disease. J Physiol Sci. 2015; 65:25-35.","DOI":"10.1007\/s12576-014-0331-x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Muller N, Hofschuster E, Ackenheil M, Eckstein R. T-cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy. Acta Psychiatr Scand. 1993; 87:66-71.","DOI":"10.1111\/j.1600-0447.1993.tb03331.x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Schlaaff K, Dobrowolny H, Frodl T, Mawrin C, Gos T, Steiner J, Bogerts B. Increased densities of T and B lymphocytes indicate neuroinflammation in subgroups of schizophrenia and mood disorder patients. Brain Behav Immun. 2020; 88:497-506.","DOI":"10.1016\/j.bbi.2020.04.021"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kazama I, Senzaki M. Does immunosuppressive property of non-steroidal anti-inflammatory drugs (NSAIDs) reduce COVID-19 vaccine-induced systemic side effects? Drug Discov Ther. 2021; 15:278-280.","DOI":"10.5582\/ddt.2021.01094"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kazama I, Baba A, Matsubara M, Endo Y, Toyama H, Ejima Y. Benidipine suppresses <i>in situ<\/i> proliferation of leukocytes and slows the progression of renal fibrosis in rat kidneys with advanced chronic renal failure. Nephron Experimental nephrology. 2014; 128:67-79.","DOI":"10.1159\/000368080"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Wang X, Li G, Guo J, Zhang Z, Zhang S, Zhu Y, Cheng J, Yu L, Ji Y, Tao J. Kv1.3 Channel as a key therapeutic target for neuroinflammatory diseases: State of the art and beyond. Front Neurosci. 2019; 13:1393.","DOI":"10.3389\/fnins.2019.01393"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Hong J, Bang M. Anti-inflammatory strategies for schizophrenia: A review of evidence for therapeutic applications and drug repurposing. Clin Psychopharmacol Neurosci. 2020; 18:10-24.","DOI":"10.9758\/cpn.2020.18.1.10"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Cakici N, van Beveren NJM, Judge-Hundal G, Koola MM, Sommer IEC. An update on the efficacy of anti-inflammatory agents for patients with schizophrenia: a meta-analysis. Psychol Med. 2019; 49:2307-2319.","DOI":"10.1017\/S0033291719001995"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kazama I, Maruyama Y, Murata Y. Suppressive effects of nonsteroidal anti-inflammatory drugs diclofenac sodium, salicylate and indomethacin on delayed rectifier K<sup>+<\/sup>-channel currents in murine thymocytes. Immunopharmacol Immunotoxicol. 2012; 34:874-878.","DOI":"10.3109\/08923973.2012.666249"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Kazama I, Baba A, Maruyama Y. HMG-CoA reductase inhibitors pravastatin, lovastatin and simvastatin suppress delayed rectifier K<sup>+<\/sup>-channel currents in murine thymocytes. Pharmacol Rep. 2014; 66:712-717.","DOI":"10.1016\/j.pharep.2014.03.002"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kazama I, Tamada T, Tachi M. Usefulness of targeting lymphocyte Kv1.3-channels in the treatment of respiratory diseases. Inflamm Res. 2015; 64:753-765.","DOI":"10.1007\/s00011-015-0855-4"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Baba A, Tachi M, Maruyama Y, Kazama I. Suppressive effects of diltiazem and verapamil on delayed rectifier K<sup>+<\/sup>-channel currents in murine thymocytes. Pharmacol Rep. 2015; 67:959-964.","DOI":"10.1016\/j.pharep.2015.01.009"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Han S, Yi H, Yin SJ, Chen ZY, Liu H, Cao ZJ, Wu YL, Li WX. Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease. J Biol Chem. 2008; 283:19058-19065.","DOI":"10.1074\/jbc.M802054200"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/16\/2\/16_2022.01031\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T04:47:44Z","timestamp":1653108464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/16\/2\/16_2022.01031\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,30]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2022.01031","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,30]]},"article-number":"2022.01031"}}